| Name | Title | Contact Details |
|---|
BioStar Ventures continues to build a solid track record as an early-stage, value-added venture investor in disruptive cardiovascular and orthopaedic medical technologies by combining the insight of seasoned venture capitalists with the expertise of world-renowned medical thought leaders in clinical practice to attract unique deal flow, mitigate investment risk, optimize product development, and secure successful exit.
SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.
STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.